FDA inspection
No Miss Ltd., Inc.: FDA inspection ending Jun 15, 2005
FDA inspection 381697 · Voluntary Action Indicated (VAI) · Boca Raton, FL
Key facts
| Inspection ID | 381697 |
|---|---|
| Firm | No Miss Ltd., Inc. |
| FEI number | 1000113136 |
| Address | 6401 E Rogers Cir |
| City | Boca Raton |
| State | FL |
| ZIP | 33487-2602 |
| Fiscal year | 2005 |
| Inspection end date | Jun 15, 2005 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- 10–99 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data